These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 34942189)
1. Organoids as research models for hepatocellular carcinoma. Yu JH; Ma S Exp Cell Res; 2022 Feb; 411(1):112987. PubMed ID: 34942189 [TBL] [Abstract][Full Text] [Related]
2. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160 [TBL] [Abstract][Full Text] [Related]
3. Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance. Liu J; Li P; Wang L; Li M; Ge Z; Noordam L; Lieshout R; Verstegen MMA; Ma B; Su J; Yang Q; Zhang R; Zhou G; Carrascosa LC; Sprengers D; IJzermans JNM; Smits R; Kwekkeboom J; van der Laan LJW; Peppelenbosch MP; Pan Q; Cao W Cell Mol Gastroenterol Hepatol; 2021; 11(2):407-431. PubMed ID: 32932015 [TBL] [Abstract][Full Text] [Related]
4. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids. Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334 [TBL] [Abstract][Full Text] [Related]
5. Plasma-derived extracellular matrix for xenofree and cost-effective organoid modeling for hepatocellular carcinoma. El-Derby AM; Khedr MA; Ghoneim NI; Gabr MM; Khater SM; El-Badri N J Transl Med; 2024 May; 22(1):487. PubMed ID: 38773585 [TBL] [Abstract][Full Text] [Related]
6. Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Nuciforo S; Fofana I; Matter MS; Blumer T; Calabrese D; Boldanova T; Piscuoglio S; Wieland S; Ringnalda F; Schwank G; Terracciano LM; Ng CKY; Heim MH Cell Rep; 2018 Jul; 24(5):1363-1376. PubMed ID: 30067989 [TBL] [Abstract][Full Text] [Related]
7. Updates on Organoid Model for the Study of Liver Cancer. El-Khobar KE; Sukowati CHC Technol Cancer Res Treat; 2023; 22():15330338231154090. PubMed ID: 36788421 [TBL] [Abstract][Full Text] [Related]
8. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation. Cho K; Ro SW; Lee HW; Moon H; Han S; Kim HR; Ahn SH; Park JY; Kim DY Hepatology; 2021 Nov; 74(5):2605-2621. PubMed ID: 34101869 [TBL] [Abstract][Full Text] [Related]
9. Liver Organoids as an In Vitro Model to Study Primary Liver Cancer. De Siervi S; Turato C Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901961 [TBL] [Abstract][Full Text] [Related]
10. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056 [TBL] [Abstract][Full Text] [Related]
11. The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy. Guan Y; Chen X; Wu M; Zhu W; Arslan A; Takeda S; Nguyen MH; Majeti R; Thomas D; Zheng M; Peltz G J Hepatol; 2020 Apr; 72(4):746-760. PubMed ID: 31760071 [TBL] [Abstract][Full Text] [Related]
12. Organoid technology in cancer precision medicine. Xia X; Li F; He J; Aji R; Gao D Cancer Lett; 2019 Aug; 457():20-27. PubMed ID: 31078736 [TBL] [Abstract][Full Text] [Related]
13. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture. Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078 [TBL] [Abstract][Full Text] [Related]
14. Personalized therapy for hepatocellular carcinoma: Where are we now? Chan SL; Wong AM; Lee K; Wong N; Chan AK Cancer Treat Rev; 2016 Apr; 45():77-86. PubMed ID: 26995632 [TBL] [Abstract][Full Text] [Related]
15. Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers. Li L; Selaru FM Adv Cancer Res; 2022; 156():319-341. PubMed ID: 35961704 [TBL] [Abstract][Full Text] [Related]
16. Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery. Zhang CY; Zhang XF; Yuan J; Gong YF; Tang H; Guo WY; Li TY; Li CW; Tang YQ; Ma NF; Liu M J Vis Exp; 2023 Aug; (198):. PubMed ID: 37607105 [TBL] [Abstract][Full Text] [Related]
17. Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy. Chen L; Wei X; Gu D; Xu Y; Zhou H Cancer Lett; 2023 Feb; 555():216048. PubMed ID: 36603689 [TBL] [Abstract][Full Text] [Related]
18. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine. Qu S; Xu R; Yi G; Li Z; Zhang H; Qi S; Huang G Mol Biomed; 2024 Feb; 5(1):6. PubMed ID: 38342791 [TBL] [Abstract][Full Text] [Related]
19. Ter-cell, A New Target for Hepatocellular Carcinoma Therapy. Cen X; Cheng K Chembiochem; 2018 Nov; 19(21):2254-2256. PubMed ID: 30136761 [TBL] [Abstract][Full Text] [Related]
20. Microenvironment of a tumor-organoid system enhances hepatocellular carcinoma malignancy-related hallmarks. Wang Y; Takeishi K; Li Z; Cervantes-Alvarez E; Collin de l'Hortet A; Guzman-Lepe J; Cui X; Zhu J Organogenesis; 2017 Jul; 13(3):83-94. PubMed ID: 28548903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]